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Abstract
Background: Experimental studies have shown that luminal antigens are involved in chronic
intestinal inflammatory disorders such as Crohn's disease and ulcerative colitis. Alteration of the
intestinal microflora by antibiotic or probiotic therapy may induce and maintain remission. The aim
of this randomized, placebo-controlled trial was to determine the effect of oral Lactobacillus GG (L.
GG)  to induce or maintain medically induced remission.
Methods: Eleven patients with moderate to active Crohn's disease were enrolled in this trial to
receive either L. GG (2 × 109 CFU/day) or placebo for six months. All patients were started on a
tapering steroid regime and received antibiotics for the week before the probiotic/placebo
medication was initiated. The primary end point was sustained remission, defined as freedom from
relapse at the 6 months follow-up visit. Relapse was defined as an increase in CDAI of >100 points.
Results: 5/11 patients finished the study, with 2 patients in each group in sustained remission. The
median time to relapse was 16 ± 4 weeks in the L. GG group and 12 ± 4.3 weeks in the placebo
group (p = 0.5).
Conclusion: In this study we could not demonstrate a benefit of L. GG in inducing or maintaining
medically induced remission in CD.
Background
Chronic inflammatory bowel diseases (IBD) such as
Crohn's disease (CD) and ulcerative colitis (UC) appear
to be the result of an unbalanced immune response to
luminal antigens. There is evidence from clinical trials and
animal experiments that alteration of the composition of
the intestinal microflora by antibiotic treatment can
induce and maintain remission [1].
Recently, probiotic microorganisms received much scien-
tific attention due to reports of successful treatment of var-
ious intestinal, mainly infectious disorders [2].
Furthermore, there are reports on successful induction
and maintenance of remission of chronic pouchitis [3]
and ulcerative colitis [4], but treatment of Crohn's disease
with probiotic preparations proved difficult [5-7]. While
L. GG and E. coli strain Nissle 1917 were ineffective in
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preventing recurrence after curative resection in CD or
maintaining medically induced remission [5,6], the pro-
biotic compound VSL#3 together with antibiotic therapy
was beneficial in prevention of post-operative recurrence
of Crohn's disease [8], and L. GG led to a significant clin-
ical improvement in pediatric CD patients [7], but no
clinical trials were performed to test the ability to main-
tain a medically induced remission in adult CD.
The mechanisms by which probiotic microorganisms
mediate their therapeutic effects are not fully understood.
Probiotic microorganisms exert their action through a
temporary modulation of the intestinal bowel flora [9,10]
and by that might influence the intestinal immune system
[11,12]. In vitro, lactobacilli induce the secretion of a vari-
ety of cytokines [13-16], and in vivo, these microorgan-
isms appear to shift a Th1-mediated immune response to
intestinal bacteria to a Th-2-dominated response [11,12].
Since especially CD appears to be a Th1-driven disease,
with an overly aggressive immune response to the intesti-
nal microflora, probiotics should theoretically be able to
alter the course of the disease [17,18].
The aim of this study was therefore to evaluate the effect
of oral L. GG on induction and maintenance of remission
in patients with moderate to active CD.
Methods
Patients
A total of 11 patients were with moderate to active
Crohn's disease (CDAI 150–300) were enrolled in this
randomized, double-blind, placebo-controlled trial. The
ethical review panel of the University of Regensburg,
School of Medicine approved the study protocol and
informed consent was obtained prior to enrollment in the
trial. At the beginning of the study, both groups were com-
parable in demographic characteristics (age, gender), in
CDAI (269 ± 44 vs. 304 ± 27), and c-reactive protein
(CRP; 32 mg/l ± 11 mg/l vs. 54 mg/l ± 21 mg/l).
Treatment protocol
The study profile is outlined in Figure 1. Following base-
line examination to determine eligibility, all patients were
started on oral antibiotic treatment (ciprofloxacin 500 mg
bd, metronidazole 250 mg tds) to be continued for 2
weeks. Following week 1, the patients were randomized to
receive either L. GG (n = 5)(2 × 109 CFU/day; CAG Func-
tional Foods, Omaha, NE) or placebo (n = 6). The probi-
otic therapy was continued for 6 months.
For the first 12 weeks, a standard tapering regime of corti-
costeroids, beginning with 60 mg p.o. per day was admin-
istered. Follow up visits were carried out after 2, 4, 8, 12,
18 weeks and after 6 months.
Statistical analysis
The primary end point was reached at 6 months in sus-
tained remission or at time of relapse. Secondary end
points were tolerability, possible side effects of the study
medication and impact on c-reactive protein. Relapse was
defined as an increase in CDAI of >100 points. Statistical
Outline of the study protocol Figure 1
Outline of the study protocol
Time to relapse as depicted by Kaplan-Meier survival  estimates Figure 2
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analyses were performed using a test for normality, fol-
lowed by a t-test or a Mann-Whitney Rank Sum Test. The
probability for relapse was calculated using the Kaplan-
Meier method (SPSS for windows, Version 11.0).
Due to slow inclusion rates and negative reports of the
effect of L. GG in maintenance of remission in CD, the
enrolment of patients was stopped prematurely, resulting
in a small study population.
Results
Apart from mild bloating, no significant side effects were
reported.
A total of 11 patients were enrolled into the trial. 5/11
patients finished the study period, with 2 patients in each
group in sustained remission (table 1). Four patients in
the verum group and 5 patients in the placebo group
reached remission during the observation period but 2
patients receiving L. GG and 3 patients on placebo
relapsed.
In the verum group, 2 patients had signs of a clinical
relapse in week 12, and 1 patient still had active disease at
the end of the trial. One of the patients with signs of a clin-
ical relapse developed an intestinal abscess, but no L. GG
could be identified by culture.
In the placebo arm, 2 patients showed signs of a relapse in
week 4 and respectively in week 8, while another patient
relapsed in week 12. One patient had to be taken out of
the trial due to ileocaecal resection in week 8.
The mean time to relapse was 16 ± 4 weeks in the L. GG
group and 12 ± 4.3 weeks in the placebo group (p = 0.5)
(Fig. 2). All other parameters (CDAI, CRP) were not
altered in both groups.
Discussion
There is mounting evidence from clinical trials and ani-
mal studies, demonstrating the beneficial effects of probi-
otic preparations in the treatment chronic intestinal
disorders such as ulcerative colitis and pouchitis. How-
ever, in Crohn's disease, there are conflicting reports in the
literature. Saccharomyces boulardii and the probiotic prepa-
ration VSL#3 were promising in clinical trials in the main-
tenance of medically or surgically induced remission of
CD [19-21], but E. coli Nissle 1917 was not beneficial in
Crohn's disease [5]. Gupta et al. conducted a small open
trial using L. GG in children with Crohn's disease and was
able to document clinical improvement [7]. However, in
a larger follow-up study, Bousvarous et al. were not able
to show an effect of adding L. GG to standard mainte-
nance therapy in children with Crohn's disease [21]. In a
recent trial by Prantera et al. L. GG was added to postop-
erative treatment to maintain remission in Crohn's dis-
ease with no clinical benefits seen [6].
In our trial, we could not demonstrate a benefit of L. GG
in inducing remission in CD. While this observation
could be due to the short observation period of six
months, in 2/5 patients of the L. GG group, relapse
occurred in week 12, at the end of the tapering steroid
medication. This was also seen in the placebo group,
where two patients relapsed at week 4 or respectively week
8 and therefore is probably due to the fact of reducing the
steroid medication. Only 1/5 patients in the placebo arm
went into remission and relapse at the end of the study
period. 2/5 patients receiving L. GG and 2/6 patients in
the placebo group achieved and maintained remission.
Due to the small sample size and 1 patient not finishing
the trial in the placebo arm, we are not able to comment
on the effect of L. GG to maintain remission once the ster-
oid medication had ceased.
Conclusions
In this study we could not demonstrate a benefit of L. GG
in inducing or maintaining medically induced remission
in CD.
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Table 1: Study characteristics
pts. CDAI* CRP* in mg/l remission sustained remission Relapse mean time to relapse (in weeks)
L. GG n = 5 269 ± 44 32 ± 11 4/5 2/4 2/4 16 ± 4
Placebo n = 6 304 ± 27 54 ± 21 5/6 2/5 3/5 12 ± 4.3**
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